Tulsa Wealth Advisors INC Invests $804,000 in Edwards Lifesciences Corporation $EW

Tulsa Wealth Advisors INC purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 9,430 shares of the medical research company’s stock, valued at approximately $804,000.

A number of other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth about $266,000. NewEdge Advisors LLC grew its stake in shares of Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares during the period. Sei Investments Co. increased its holdings in shares of Edwards Lifesciences by 16.7% during the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after buying an additional 58,988 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after buying an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina raised its position in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after buying an additional 1,065 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on EW. Truist Financial set a $90.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. BTIG Research lifted their target price on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Robert W. Baird upped their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Finally, Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a report on Wednesday, April 1st. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $87.51 on Friday. The company’s 50 day simple moving average is $83.39 and its 200-day simple moving average is $83.14. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $89.60. The company has a market capitalization of $50.39 billion, a price-to-earnings ratio of 46.55, a price-to-earnings-growth ratio of 2.19 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter last year, the company posted $0.64 EPS. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the sale, the vice president owned 33,934 shares in the company, valued at approximately $2,816,861.34. The trade was a 2.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the sale, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. This represents a 24.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 81,038 shares of company stock valued at $6,683,255 over the last three months. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.